Infectious Disease Diagnostics Market Size, Global Industry Outlook, Detailed Analysis and Forecast 2022-2027
The global infectious disease diagnostics market size is projected to reach USD 33.1 billion by 2027 from USD 35.5 billion in 2022, at a -1.4% CAGR. Growth in the infectious disease diagnostics industry is mainly driven by factors such as the rising prevalence of infectious diseases and the rising funding for R&D in infectious disease diagnostics. The growing awareness for early disease diagnosis, shift in focus from centralized laboratories to decentralized point-of-care testing and rising technological advancements are factors supporting the growth of this market.
Request For a Free Sample Report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=116764589
Infectious diseases are caused by pathogens such as bacteria, viruses, fungi, or parasites. Infectious diseases are spread from person to person through direct contact or indirectly through insect bites or other carriers such as food, soil, water, and air.
This study involved four major activities in estimating the current size of the infectious disease diagnostics market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size.
Key Market Players
The major players operating in this market are Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux SA (France), Siemens Healthineers AG (Germany), Danaher Corporation (US), Becton, Dickinson and Company (US), PerkinElmer, Inc. (US), Hologic, Inc. (US), QIAGEN N.V. (Netherlands), Grifols S.A. (Spain), DiaSorin S.p.A (Italy), Bio-Rad Laboratories, Inc. (US), Sysmex Corporation (Japan), Ortho Clinical Diagnostics Holdings plc (US), Quidel Corporation (US), Meridian Bioscience (US), Genetic Signatures Ltd. (Australia), OraSure Technologies (US), Trinity Biotech Plc. (Ireland), Chembio Diagnostic Systems (US), Seegene, Inc. (South Korea), Co-Diagnostics (US), ELITechGroup (France), Epitope Diagnostics (US), Trivitron Healthcare (India), Meril Life Sciences Pvt. Ltd. (India), InBios International (US), Vela Diagnostics (Singapore) and Uniogen Oy (Finland).
North America is the largest regional market for infectious disease diagnostics market
The infectious disease diagnostics market is segmented into five regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest share of the infectious disease diagnostics market. The large share of this region can be attributed to the highly developed healthcare system in the US and Canada, the presence of many leading national clinical laboratories, and the easy accessibility to technologically advanced instruments.
Inquire for a Discount on this Premium Report @ https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=116764589
This report categorizes the infectious disease diagnostics market into the following segments and subsegments:
By Product
- Reagents, Kits, and Consumables
- Instruments
- Software & Services
By Type of Testing
- Laboratory Testing
- POC Testing
By Technology
- Immunodiagnostics
- Clinical Microbiology
- PCR
- INAAT
- DNA Sequencing & NGS
- DNA Microarray
- Other technologies
By Disease Type
- COVID-19
- HIV
- Hospital-acquired Infections
- Hepatitis
- Chlamydia Trachomatis
- Neisseria Gonorrhea
- HPV
- Tuberculosis
- Influenza
- Syphilis
- Mosquito-borne Diseases
- Other Infectious Diseases
By End User
- Diagnostic Laboratories
- Hospitals & Clinics
- Academic Research Institutes
- Other End Users
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Recent Developments
- In November 2022, Roche Diagnostics Launched cobas 5800 system.
Access Full Report along with TOC @ https://www.marketsandmarkets.com/Market-Reports/infectious-disease-diagnostics-market-116764589.html
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian